Probiotics to prevent cognitive dysfunction

USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.

Mesembrine Crystalline Salt Patent Grant

USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.

Thiosemicarbazates and Uses Thereof

The USPTO granted patent US12595233B2 to The Feinstein Institutes for Medical Research on April 7, 2026. The patent covers thiosemicarbazates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides, along with methods for their synthesis and applications in drug discovery, diagnosis, inhibition, prevention, and treatment of diseases. The patent names Yousef Al-Abed and Ahmad Altiti as inventors.

2,6-dioxo-3,6-dihydropyrimidine compound, bactericide, nematicide, and antifungal agent

USPTO granted patent US12593845B2 to Nippon Soda Co., Ltd. on April 7, 2026, covering a 2,6-dioxo-3,6-dihydropyrimidine compound for use as an agricultural and horticultural bactericide, nematicide, and medical/veterinary antifungal agent. The patent contains 4 claims and names 9 inventors including Takaaki Teranishi and Hajime Shimomura.

STAT3 inhibitor prodrug patent compositions

USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.

Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors

USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.

MDM2 Inhibitor Patent Granted to Bahcesehir University

The USPTO granted Bahcesehir University Patent No. US12595232B2 for a novel Mouse Double Minute 2 (MDM2) inhibitor compound. The patent covers formula (I) compounds or pharmaceutically acceptable derivatives for inhibiting MDM2 activity. Application No. 17904403 was filed February 16, 2021, and the patent contains 2 claims.

Rovi granted patent for schizophrenia injectable depot composition

USPTO granted patent US12594236B2 to Laboratorios Farmaceuticos Rovi, S.A. for a method of treating acute exacerbation of schizophrenia using a long-acting injectable depot composition containing risperidone. The patent covers a formulation achieving substantial PANSS score reduction within eight days and lasting up to four weeks without requiring loading doses or oral supplementation. The patent has 23 claims and was filed May 18, 2022 under application No. 17747422.

VANILLA SUEDE trademark opposition dismissed

The USPTO Trademark Trial and Appeal Board dismissed Opposition No. 91300846, where Byredo AB challenged Sunny Tradebark, LLC's VANILLA SUEDE trademark application. The opposition was dismissed without prejudice, meaning Byredo could potentially refile. The TTAB decision carries case number 91300846.

Explorer Passport Trademark Opposition

USPTO Trademark Trial and Appeal Board suspended opposition proceeding TTAB91301611 involving Eastern National (Plaintiff) versus iD MKG. LLC (Defendant) concerning trademark THE EXPLORER'S PASSPORT. The proceeding is suspended pending disposition of an outstanding motion. The opposition was originally filed on September 10, 2025.